ESR1 and triple-negative breast carcinoma: Triple-negative breast cancers (TNBCs, lacking the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor-2 (HER2)) can benefit from this metabolic switch and, consistently, can be targeted by novel therapeutic compounds called glycolysis inhibitors.